opentargets/clinical_trial_reason_to_stop · Datasets at Hugging Face

text stringlengths 4 164	label_descriptions sequence	Another_Study bool 2 classes	Business_Administrative bool 2 classes	Covid19 bool 2 classes	Endpoint_Met bool 2 classes	Ethical_Reason bool 2 classes	Insufficient_Data bool 2 classes	Insufficient_Enrollment bool 2 classes	Interim_Analysis bool 2 classes	Invalid_Reason bool 2 classes	Logistics_Resources bool 2 classes	Negative bool 2 classes	No_Context bool 2 classes	Regulatory bool 2 classes	Safety_Sideeffects bool 2 classes	Study_Design bool 2 classes	Study_Staff_Moved bool 2 classes	Success bool 2 classes
Institution decided on starting a new protocol of sedation, with another methods and thatåÀs Ê why this study has not started.	[ "Study_Design", "Invalid_Reason" ]	false	false	false	false	false	false	false	false	true	false	false	false	false	false	true	false	false
Institution in Canada is conducting a similar clinical trial with potential of validating use.	[ "Another_Study" ]	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Insufficient # subjects available for 2nd group; evaluating alternate study site	[ "Insufficient_Enrollment", "Study_Staff_Moved" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	true	false
Insufficient Accrual	[ "Insufficient_Enrollment", "Insufficient_Data" ]	false	false	false	false	false	true	true	false	false	false	false	false	false	false	false	false	false
Insufficient Data Collected	[ "Insufficient_Data" ]	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false	false
Insufficient Enrollment	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Insufficient Funds and Inadequate Subject Recruitment	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Insufficient accrual	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Insufficient accrual of population likely to benefit; progression in 6 patients	[ "Insufficient_Enrollment", "Negative" ]	false	false	false	false	false	false	true	false	false	false	true	false	false	false	false	false	false
Insufficient dose for MRI scanning	[ "Logistics_Resources" ]	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false
Insufficient enrollment	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Insufficient enrollment rate	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Insufficient enrollment to justify keeping open.	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Insufficient evidence of the clinical effectiveness of cangrelor	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Insufficient financial support to continue; lack of efficacy	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Insufficient findings for data analysis	[ "Insufficient_Data" ]	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false	false
Insufficient funding	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Insufficient funding to complete with low enrollment rate	[ "Logistics_Resources", "Business_Administrative", "Insufficient_Enrollment" ]	false	true	false	false	false	false	true	false	false	true	false	false	false	false	false	false	false
Insufficient funds	[ "Business_Administrative", "Logistics_Resources" ]	false	true	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false
Insufficient funds available	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Insufficient interest and recruitment - study ended prematurely by investigators	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Insufficient number of baseline eligible patient	[ "Study_Design", "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	true	false	false
Insufficient number of inclusion	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Insufficient participants.	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Insufficient patient enrolled	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Insufficient patient enrollment	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Insufficient patient recruitment	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Insufficient patients who met inclusion criteria	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Insufficient rate of volunteer accrual.	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Insufficient recruitment	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Insufficient recruitment in a reasonable time + expiration of study medication	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Insufficient recruitment of study patients	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Insufficient recruitment rate	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Insufficient recruitment, funding terminated from sponsor	[ "Business_Administrative", "Insufficient_Enrollment" ]	false	true	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Insufficient recruitment.	[ "Insufficient_Enrollment", "Study_Design" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	true	false	false
Insufficient resources necessary for completion.	[ "Logistics_Resources" ]	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false
Insufficient response rate	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Insufficient study participants	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Insufficient subject accrual	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Insufficient subject availability/findings for data analysis	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Insufficient subject enrollment	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Insufficient subject recruitment.	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Insuficient clinical activity.	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Insulin-HF study was prematurely ended due principally to low recruitment rate.	[ "Insufficient_Enrollment" ]	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false	false
Intended length of study ended	[ "Invalid_Reason" ]	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false
Intepirdine did't meet primary efficacy endpoints in lead-in study RVT-101-3001	[ "Another_Study", "Negative" ]	true	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Interim Analysis	[ "Interim_Analysis" ]	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false
Interim Analysis and review by Data Safety Monitoring Board	[ "Interim_Analysis" ]	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false
Interim Analysis ongoing	[ "Interim_Analysis" ]	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false
Interim Analysis result indicated the study will not show a significant benefit of the study medication on the primary endpoint.	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Interim Analysis: Optimization of study design required.	[ "Study_Design" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false
Interim analyses showed statistically and clinically significant results.	[ "Success" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true
Interim analysis	[ "Interim_Analysis" ]	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false	false
Interim analysis has shown that the objectives of this study can not be reached	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Interim analysis indicated that sample size of study patients had to be highly increased to obtain significant outcomes.	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Interim analysis of Primary Endpoint completed	[ "Invalid_Reason" ]	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false	false
Interim analysis of data failed to meet primary endpoint.	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Interim analysis of the present study showed a significant decrease in mortality rate (p= 0.04) as well as in the number of days at the ICU p=0.0002.	[ "Endpoint_Met" ]	false	false	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false
Interim analysis results did not meet criteria for second stage of trial	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Interim analysis results revealed substantial increase of patient number, with unfeasibleÊ study prolongation.	[ "Study_Design", "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	true	false	false
Interim analysis showed a significant reduction in the pain scores	[ "Success" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true
Interim analysis showed efficacy less than 2.5%.	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Interim analysis showed greater variablility in NT-proBNP findings than anticipated.	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Interim analysis showed inadequate efficacy of bifeprunox	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Interim analysis showed more LCFs in one of the treatment arms	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Interim analysis showed no difference in outcome between treatment groups.	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Interim analysis showed no drug efficacy.	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Interim analysis showed significant results, thus study was stopped"	[ "Endpoint_Met" ]	false	false	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false
Interim analysis suggested a trend favoring ecallantide; observed response rate to placebo wasÊ substantially higher than described in medical literature.	[ "Success" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true
Interim analysis, infliximab did not reduce number of first relapses in GCA or cumulative glucocorticosteroid dosage"	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Interim analysis-DSMB stated good safety profile but lack of efficacy	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Interim data analysis showed no effect between treatment groups	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Interim data indicated that subjects exhibited no meaningful allergic disease during the first ragweed season, making it impossible to measure treatment effect."	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Interim efficacy analysis indicated it would be futile to continue study.	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Interim results of another trial showed inferior activity of treatment	[ "Another_Study" ]	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Interim review indicated that the dose selected was too high for diabetics	[ "Study_Design" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false
Interim safety analysis	[ "Safety_Sideeffects" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false	false
Internal Business Decision	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Internal Study team decision not to proceed.	[ "Business_Administrative", "No_Context" ]	false	true	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false
Internal business decision	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Internal problems	[ "No_Context" ]	false	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false
Interruption of business relations between Study Sponsor and Device Manufacturer	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Intervention did not appear to be effective in most enrolled patients.	[ "Negative" ]	false	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false
Intervention/interactions are temporarily paused due to COVID-19 and are expected to resume.	[ "Covid19" ]	false	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Investigation of adverse events for a study in Germany using erythropoetin	[ "Another_Study" ]	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Investigational product unavailable due to manufacturing issues	[ "Logistics_Resources" ]	false	false	false	false	false	false	false	false	false	true	false	false	false	false	false	false	false
Investigations on a Suspected Unexpected Serious Adverse Reaction (SUSAR)	[ "Safety_Sideeffects" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false	false
Investigations on a Suspected Unexpected Serious Adverse Reaction (SUSAR) in another trial (Phase II Multiple Myeloma trial EMR63325-008)	[ "Another_Study" ]	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Investigator Resigned	[ "Study_Staff_Moved" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false
Investigator Retired.	[ "Study_Staff_Moved" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false
Investigator closed study and left VAMC.	[ "Study_Staff_Moved" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false
Investigator decided it was not feasible to conduct this study	[ "Study_Design" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false	false
Investigator decided to withdraw participation in the study	[ "Business_Administrative" ]	false	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Investigator initiated hold due to animal toxicity results in another study; then changed study design so it no longer fit the description of this study.	[ "Another_Study" ]	true	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false
Investigator is leaving Dartmouth	[ "Study_Staff_Moved" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false
Investigator left UTHSC-Houston	[ "Study_Staff_Moved" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false
Investigator left institution	[ "Study_Staff_Moved" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false
Investigator left institution. 7 patients accrued and there is insufficient data to analyze.	[ "Insufficient_Data", "Insufficient_Enrollment", "Study_Staff_Moved" ]	false	false	false	false	false	true	true	false	false	false	false	false	false	false	false	true	false
Investigator left the institution	[ "Study_Staff_Moved" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false
Investigator left the institution, another PI has not been named."	[ "Study_Staff_Moved" ]	false	false	false	false	false	false	false	false	false	false	false	false	false	false	false	true	false

Institution decided on starting a new protocol of sedation, with another methods and thatåÀs Ê why this study has not started.

[ "Study_Design", "Invalid_Reason" ]

false

true

false

true

false

Institution in Canada is conducting a similar clinical trial with potential of validating use.

[ "Another_Study" ]

true

false

Insufficient # subjects available for 2nd group; evaluating alternate study site

[ "Insufficient_Enrollment", "Study_Staff_Moved" ]

false

true

false

true

false

Insufficient Accrual

[ "Insufficient_Enrollment", "Insufficient_Data" ]

false

true

false

Insufficient Data Collected

[ "Insufficient_Data" ]

false

true

false

Insufficient Enrollment

[ "Insufficient_Enrollment" ]

false

true

false

Insufficient Funds and Inadequate Subject Recruitment

[ "Business_Administrative" ]

false

true

false

Insufficient accrual

[ "Insufficient_Enrollment" ]

false

true

false

Insufficient accrual of population likely to benefit; progression in 6 patients

[ "Insufficient_Enrollment", "Negative" ]

false

true

false

true

false

Insufficient dose for MRI scanning

[ "Logistics_Resources" ]

false

true

false

Insufficient enrollment

[ "Insufficient_Enrollment" ]

false

true

false

Insufficient enrollment rate

[ "Insufficient_Enrollment" ]

false

true

false

Insufficient enrollment to justify keeping open.

[ "Insufficient_Enrollment" ]

false

true

false

Insufficient evidence of the clinical effectiveness of cangrelor

[ "Negative" ]

false

true

false

Insufficient financial support to continue; lack of efficacy

[ "Business_Administrative" ]

false

true

false

Insufficient findings for data analysis

[ "Insufficient_Data" ]

false

true

false

Insufficient funding

[ "Business_Administrative" ]

false

true

false

Insufficient funding to complete with low enrollment rate

[ "Logistics_Resources", "Business_Administrative", "Insufficient_Enrollment" ]

false

true

false

true

false

true

false

Insufficient funds

[ "Business_Administrative", "Logistics_Resources" ]

false

true

false

true

false

Insufficient funds available

[ "Business_Administrative" ]

false

true

false

Insufficient interest and recruitment - study ended prematurely by investigators

[ "Insufficient_Enrollment" ]

false

true

false

Insufficient number of baseline eligible patient

[ "Study_Design", "Insufficient_Enrollment" ]

false

true

false

true

false

Insufficient number of inclusion

[ "Insufficient_Enrollment" ]

false

true

false

Insufficient participants.

[ "Insufficient_Enrollment" ]

false

true

false

Insufficient patient enrolled

[ "Insufficient_Enrollment" ]

false

true

false

Insufficient patient enrollment

[ "Insufficient_Enrollment" ]

false

true

false

Insufficient patient recruitment

[ "Insufficient_Enrollment" ]

false

true

false

Insufficient patients who met inclusion criteria

[ "Insufficient_Enrollment" ]

false

true

false

Insufficient rate of volunteer accrual.

[ "Insufficient_Enrollment" ]

false

true

false

Insufficient recruitment

[ "Insufficient_Enrollment" ]

false

true

false

Insufficient recruitment in a reasonable time + expiration of study medication

[ "Insufficient_Enrollment" ]

false

true

false

Insufficient recruitment of study patients

[ "Insufficient_Enrollment" ]

false

true

false

Insufficient recruitment rate

[ "Insufficient_Enrollment" ]

false

true

false

Insufficient recruitment, funding terminated from sponsor

[ "Business_Administrative", "Insufficient_Enrollment" ]

false

true

false

true

false

Insufficient recruitment.

[ "Insufficient_Enrollment", "Study_Design" ]

false

true

false

true

false

Insufficient resources necessary for completion.

[ "Logistics_Resources" ]

false

true

false

Insufficient response rate

[ "Insufficient_Enrollment" ]

false

true

false

Insufficient study participants

[ "Insufficient_Enrollment" ]

false

true

false

Insufficient subject accrual

[ "Insufficient_Enrollment" ]

false

true

false

Insufficient subject availability/findings for data analysis

[ "Insufficient_Enrollment" ]

false

true

false

Insufficient subject enrollment

[ "Insufficient_Enrollment" ]

false

true

false

Insufficient subject recruitment.

[ "Insufficient_Enrollment" ]

false

true

false

Insuficient clinical activity.

[ "Negative" ]

false

true

false

Insulin-HF study was prematurely ended due principally to low recruitment rate.

[ "Insufficient_Enrollment" ]

false

true

false

Intended length of study ended

[ "Invalid_Reason" ]

false

true

false

Intepirdine did't meet primary efficacy endpoints in lead-in study RVT-101-3001

[ "Another_Study", "Negative" ]

true

false

true

false

Interim Analysis

[ "Interim_Analysis" ]

false

true

false

Interim Analysis and review by Data Safety Monitoring Board

[ "Interim_Analysis" ]

false

true

false

Interim Analysis ongoing

[ "Interim_Analysis" ]

false

true

false

Interim Analysis result indicated the study will not show a significant benefit of the study medication on the primary endpoint.

[ "Negative" ]

false

true

false

Interim Analysis: Optimization of study design required.

[ "Study_Design" ]

false

true

false

Interim analyses showed statistically and clinically significant results.

[ "Success" ]

false

true

Interim analysis

[ "Interim_Analysis" ]

false

true

false

Interim analysis has shown that the objectives of this study can not be reached

[ "Negative" ]

false

true

false

Interim analysis indicated that sample size of study patients had to be highly increased to obtain significant outcomes.

[ "Negative" ]

false

true

false

Interim analysis of Primary Endpoint completed

[ "Invalid_Reason" ]

false

true

false

Interim analysis of data failed to meet primary endpoint.

[ "Negative" ]

false

true

false

Interim analysis of the present study showed a significant decrease in mortality rate (p= 0.04) as well as in the number of days at the ICU p=0.0002.

[ "Endpoint_Met" ]

false

true

false

Interim analysis results did not meet criteria for second stage of trial

[ "Negative" ]

false

true

false

Interim analysis results revealed substantial increase of patient number, with unfeasibleÊ study prolongation.

[ "Study_Design", "Negative" ]

false

true

false

true

false

Interim analysis showed a significant reduction in the pain scores

[ "Success" ]

false

true

Interim analysis showed efficacy less than 2.5%.

[ "Negative" ]

false

true

false

Interim analysis showed greater variablility in NT-proBNP findings than anticipated.

[ "Negative" ]

false

true

false

Interim analysis showed inadequate efficacy of bifeprunox

[ "Negative" ]

false

true

false

Interim analysis showed more LCFs in one of the treatment arms

[ "Negative" ]

false

true

false

Interim analysis showed no difference in outcome between treatment groups.

[ "Negative" ]

false

true

false

Interim analysis showed no drug efficacy.

[ "Negative" ]

false

true

false

Interim analysis showed significant results, thus study was stopped"

[ "Endpoint_Met" ]

false

true

false

Interim analysis suggested a trend favoring ecallantide; observed response rate to placebo wasÊ substantially higher than described in medical literature.

[ "Success" ]

false

true

Interim analysis, infliximab did not reduce number of first relapses in GCA or cumulative glucocorticosteroid dosage"

[ "Negative" ]

false

true

false

Interim analysis-DSMB stated good safety profile but lack of efficacy

[ "Negative" ]

false

true

false

Interim data analysis showed no effect between treatment groups

[ "Negative" ]

false

true

false

Interim data indicated that subjects exhibited no meaningful allergic disease during the first ragweed season, making it impossible to measure treatment effect."

[ "Negative" ]

false

true

false

Interim efficacy analysis indicated it would be futile to continue study.

[ "Negative" ]

false

true

false

Interim results of another trial showed inferior activity of treatment

[ "Another_Study" ]

true

false

Interim review indicated that the dose selected was too high for diabetics

[ "Study_Design" ]

false

true

false

Interim safety analysis

[ "Safety_Sideeffects" ]

false

true

false

Internal Business Decision

[ "Business_Administrative" ]

false

true

false

Internal Study team decision not to proceed.

[ "Business_Administrative", "No_Context" ]

false

true

false

true

false

Internal business decision

[ "Business_Administrative" ]

false

true

false

Internal problems

[ "No_Context" ]

false

true

false

Interruption of business relations between Study Sponsor and Device Manufacturer

[ "Business_Administrative" ]

false

true

false

Intervention did not appear to be effective in most enrolled patients.

[ "Negative" ]

false

true

false

Intervention/interactions are temporarily paused due to COVID-19 and are expected to resume.

[ "Covid19" ]

false

true

false

Investigation of adverse events for a study in Germany using erythropoetin

[ "Another_Study" ]

true

false

Investigational product unavailable due to manufacturing issues

[ "Logistics_Resources" ]

false

true

false

Investigations on a Suspected Unexpected Serious Adverse Reaction (SUSAR)

[ "Safety_Sideeffects" ]

false

true

false

Investigations on a Suspected Unexpected Serious Adverse Reaction (SUSAR) in another trial (Phase II Multiple Myeloma trial EMR63325-008)

[ "Another_Study" ]

true

false

Investigator Resigned

[ "Study_Staff_Moved" ]

false

true

false

Investigator Retired.

[ "Study_Staff_Moved" ]

false

true

false

Investigator closed study and left VAMC.

[ "Study_Staff_Moved" ]

false

true

false

Investigator decided it was not feasible to conduct this study

[ "Study_Design" ]

false

true

false

Investigator decided to withdraw participation in the study

[ "Business_Administrative" ]

false

true

false

Investigator initiated hold due to animal toxicity results in another study; then changed study design so it no longer fit the description of this study.

[ "Another_Study" ]

true

false

Investigator is leaving Dartmouth

[ "Study_Staff_Moved" ]

false

true

false

Investigator left UTHSC-Houston

[ "Study_Staff_Moved" ]

false

true

false

Investigator left institution

[ "Study_Staff_Moved" ]

false

true

false

Investigator left institution. 7 patients accrued and there is insufficient data to analyze.

[ "Insufficient_Data", "Insufficient_Enrollment", "Study_Staff_Moved" ]

false

true

false

true

false

Investigator left the institution

[ "Study_Staff_Moved" ]

false

true

false

Investigator left the institution, another PI has not been named."

[ "Study_Staff_Moved" ]

false

true

false